144 related articles for article (PubMed ID: 7697011)
1. Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides.
Gewirtz AM
Bone Marrow Transplant; 1994; 14 Suppl 3():S57-61. PubMed ID: 7697011
[No Abstract] [Full Text] [Related]
2. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
de Fabritiis P; Calabretta B
Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
[No Abstract] [Full Text] [Related]
3. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
4. Antisense gene therapy trials underway in patients with CML.
Oncology (Williston Park); 1996 Sep; 10(9):1411. PubMed ID: 8882929
[No Abstract] [Full Text] [Related]
5. Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation.
Yuan T; Zhou YQ; Herst CV; Reading C; Ellersen D; Etkin M; Khouri I; Kantarjian H; Talpaz M; Deisseroth A
Prog Clin Biol Res; 1992; 377():227-30. PubMed ID: 1438419
[No Abstract] [Full Text] [Related]
6. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
Gewirtz AM
Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow purging with oligodeoxynucleotides.
Gewirtz AM; Luger SM; Stadtmauer E
Blood; 1996 Aug; 88(4):1517. PubMed ID: 8695876
[No Abstract] [Full Text] [Related]
8. Bone marrow purging with antisense oligodeoxynucleotides.
Gewirtz AM
Prog Clin Biol Res; 1992; 377():215-24; discussion 225-6. PubMed ID: 1438418
[No Abstract] [Full Text] [Related]
9. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
de Fabritiis P; Petti MC; Montefusco E; De Propris MS; Sala R; Bellucci R; Mancini M; Lisci A; Bonetto F; Geiser T; Calabretta B; Mandelli F
Blood; 1998 May; 91(9):3156-62. PubMed ID: 9558370
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides.
Szczylik C; Skórski T; Malaguarnera L; Hetman J; Chen ST; Calabretta B
Folia Histochem Cytobiol; 1996; 34(3-4):129-34. PubMed ID: 8967957
[TBL] [Abstract][Full Text] [Related]
11. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
de Fabritiis P; Amadori S; Calabretta B; Mandelli F
Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
[TBL] [Abstract][Full Text] [Related]
12. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation.
de Fabritis P; Amadori S; Petti MC; Mancini M; Montefusco E; Picardi A; Geiser T; Campbell K; Calabretta B; Mandelli F
Leukemia; 1995 Apr; 9(4):662-4. PubMed ID: 7536864
[TBL] [Abstract][Full Text] [Related]
13. Ribozyme mediated therapy for chronic myelogenous leukemia.
Leopold LH; Shore SK; Newkirk T; Mangan K; Reddy EP
Prog Clin Biol Res; 1994; 389():175-82. PubMed ID: 7700900
[No Abstract] [Full Text] [Related]
14. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
15. Myb targeted therapeutics for the treatment of human malignancies.
Gewirtz AM
Oncogene; 1999 May; 18(19):3056-62. PubMed ID: 10378701
[TBL] [Abstract][Full Text] [Related]
16. [An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia].
Liu J; Jiang J; Zhang Y; Wu D; Yang G; Huang X; Wei X
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):599-601. PubMed ID: 12528561
[TBL] [Abstract][Full Text] [Related]
17. [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
Etienne G; Mahon FX
Bull Cancer; 2001 Jul; 88(7):651-8. PubMed ID: 11495816
[TBL] [Abstract][Full Text] [Related]
18. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
Ratajczak MZ; Kant JA; Luger SM; Hijiya N; Zhang J; Zon G; Gewirtz AM
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11823-7. PubMed ID: 1281545
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
Maki G; Tam YK; Berkahn L; Klingemann HG
Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
[TBL] [Abstract][Full Text] [Related]
20. Chronic myelogenous leukemia--the unfolding saga.
Goldman JM; Grosveld G; Baltimore D; Gale RP
Leukemia; 1990 Mar; 4(3):163-7. PubMed ID: 2179637
[No Abstract] [Full Text] [Related]
[Next] [New Search]
